#China #Shanghai #financial results #WuXi AppTec #CRDMO

WuXi AppTec Achieves Significant Financial Milestones in Q1-Q3 2026

WuXi AppTec, a prominent player in the pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization) sector, has reported outstanding financial outcomes for the first three-quarters of 2026, ending on September 30. Driven by robust performance across various customer products and their integrated CRDMO model, the company has successfully upgraded its earnings expectations for the year.

Financial Highlights

During the Reporting Period, WuXi AppTec generated total revenue amounting to RMB 45.54 billion, which reflects a substantial increase of 38.6% compared to the previous year. Impressively, the revenue from continuing operations surged by 46.3% YoY.

The adjustments in profit metrics are equally remarkable. The adjusted non-IFRS gross profit margin improved by 7.7 percentage points YoY, reaching 54.8%. In terms of net profits, the adjusted non-IFRS net profit saw a staggering growth of 74.4% YoY, totaling RMB 18.38 billion. Furthermore, the adjusted net profit margin rose by 8.3 points to 40.4%, while diluted earnings per share increased by 68.8% to RMB 6.21.

Another significant aspect is the increase in the backlog for continuing operations, which reached RMB 76.74 billion, showing a 36.4% YoY growth. This surge reflects the ongoing demand for their unique services and capabilities.

Management Insights

Dr. Ge Li, Chairman and CEO of WuXi AppTec, emphasized that the relationship with customers and the resulting positive impact on patients are central to the company’s ongoing success. He stated, “Our focus on delivering value through our unique CRDMO business model has positioned us to maintain momentum and achieve significant growth in revenue, profit, and cash flow. We are proud of our backlog of RMB 76.7 billion and our elevated full-year guidance.”

Dr. Li further elaborated on the company's commitment to meeting customer needs, outlining a strategy to accelerate global capacity development while ensuring operational resilience. This proactive approach aims to not only meet but exceed expectations, creating greater value for both customers and shareholders.

Shareholder Returns

In terms of dividends, WuXi AppTec has declared a total distribution of RMB 6.22 billion during Q1-Q3. This includes RMB 4.71 billion allocated for the 2025 annual dividend, along with RMB 1.51 billion for the interim dividend of 2026. This increase from RMB 1.03 billion in 2025 highlights the company's strong performance and commitment to delivering returns to its investors.

Updated Full-Year Expectations

Due to the remarkable success of their customers’ products and the effectiveness of their CRDMO model, WuXi AppTec has further revised their full-year projections. The total revenue target for 2026 has been updated to a range between RMB 61.0 billion and RMB 61.9 billion, up from the previous forecast of RMB 58.5 to RMB 60.5 billion. The company now anticipates revenue growth from continuing operations to be between 40% and 42% YoY, surpassing earlier forecasts.

In addition, the management has raised their capital expenditure forecast to approximately RMB 8.0 billion to RMB 8.5 billion, facilitating the accelerated development of global capacities, including the early initiation of the new Changzhou facility.

Alongside expansive growth and efficiency gains, the adjusted free cash flow forecast has also been increased to between RMB 14.5 billion and RMB 15.5 billion, further emphasizing their robust financial health.

About WuXi AppTec

WuXi AppTec serves as a vital partner in the pharmaceutical and life sciences arenas, delivering research and manufacturing services aimed at propelling healthcare innovations. With robust operations across Asia, Europe, and North America, the company provides integrated, all-encompassing services through its distinct CRDMO model. Committed to the ethos that every drug can be manufactured and every disease treated, WuXi AppTec collaborates with partners in over 30 countries, striving to facilitate breakthroughs that benefit patients worldwide.

For additional details visit WuXi AppTec's official site.